NCT03674177 - A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women | Biotech Hunter

Enrollment

502

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

April 16, 2019

Study Completion Date

September 2, 2019

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

GSK3888550A RSV Maternal vaccine formulation 1

Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

BIOLOGICAL

GSK3888550A RSV Maternal vaccine formulation 2

Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

BIOLOGICAL

GSK3888550A RSV Maternal vaccine formulation 3

Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

DRUG

Placebo (Normal Saline)

Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm

Trial Locations (11)

GSK Investigational Site, Rochester

GSK Investigational Site, Turku

GSK Investigational Site, Turku

GSK Investigational Site, Hamburg

GSK Investigational Site, Hanover

GSK Investigational Site, Goch

GSK Investigational Site, Mainz

GSK Investigational Site, Lenexa

GSK Investigational Site, Würzburg

GSK Investigational Site, Helsinki

GSK Investigational Site, Tampere